← ANALYST RATINGS · TIPRANKS
Amgen (AMGN): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy9 Hold0 Sell
Ratings of 15 analysts in the last 3 months · top analysts only12-month forecast
Based on 15 price targets given in the last 3 months, the average target is $418, the highest $500, the lowest $345. The average is −3.3% from the last price of $432.
Analyst ratings 44
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $442 → $488+10.4% | Buy | +12.8% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $440 → $486+10.5% | Buy | +12.4% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $432 → $477+10.4% | Buy | +10.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $419 → $462+10.3% | Hold | +6.8% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $432 → $477+10.4% | Buy | +10.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $432 → $477+10.4% | Buy | +10.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $430 | Hold | −0.6% | Reiterated | 15.10.26on TipRanks Oct 16 05:15 | +1.6%next day +0.8% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $388 → $378−2.6% | Hold | −12.6% | Reiterated | 12.10.26on TipRanks Oct 13 07:10 | +0.7%next day −1.1% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $450 → $415−7.8% | Hold | −4.0% | Reiterated | 12.10.26on TipRanks 08:50 | +0.7%next day −1.1% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $405 | Hold | −6.4% | Reiterated | 12.10.26on TipRanks 07:35 | +0.7%next day −1.1% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $317 → $328+3.5% | Sell | −24.2% | Reiterated | 12.10.26on TipRanks 06:50 | +0.7%next day −1.1% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $435 → $430−1.1% | Hold | −0.6% | Assigned | 12.10.26on TipRanks 06:10 | +0.7%next day −1.1% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $430 → $470+9.3% | Buy | +8.7% | Assigned | 09.10.26on TipRanks 08:40 | +1.2%next day +0.7% · 5 days +6.2% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $400 → $430+7.5% | Buy | −0.6% | Reiterated | 08.10.26on TipRanks 08:55 | −0.9%next day +1.2% · 5 days +6.8% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $400 → $440+10.0% | Hold | +1.7% | Assigned | 08.10.26on TipRanks 07:10 | −0.9%next day +1.2% · 5 days +6.8% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $362 → $380+5.0% | Hold | −12.1% | Reiterated | 07.10.26on TipRanks 09:05 | +2.8%next day −0.9% · 5 days +4.1% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $359 | Hold | −17.0% | Reiterated | 07.10.26on TipRanks 08:15 | +2.8%next day −0.9% · 5 days +4.1% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $457 | Buy | +5.7% | Reiterated | 05.10.26on TipRanks 07:56 | −0.7%next day −0.6% · 5 days +3.2% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $390 → $435+11.5% | Hold | +0.6% | Reiterated | 02.10.26on TipRanks 06:16 | −1.8%next day −0.7% · 5 days +1.8% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $450 → $500+11.1% | Buy | +15.6% | Reiterated | 29.09.26on TipRanks Sep 28 13:10 | +1.6%next day +1.5% · 5 days −4.8% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | — | Hold | — | Reiterated | 24.09.26on TipRanks Sep 25 04:10 | +0.1%next day +1.6% · 5 days +0.7% | ↗ |
| Unknown Analyst | Leerink Partners | — | Hold | — | Reiterated | 23.09.26on TipRanks Sep 25 04:10 | −0.3%next day +0.1% · 5 days +4.5% | ↗ |
| Unknown Analyst | Jefferies | $367 → $410+11.7% | Hold | −5.2% | Reiterated | 23.09.26on TipRanks Sep 25 04:10 | −0.3%next day +0.1% · 5 days +4.5% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $457 | Buy | +5.7% | Reiterated | 23.09.26on TipRanks 08:15 | −0.3%next day +0.1% · 5 days +4.5% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Hold | — | Reiterated | 23.09.26on TipRanks 07:55 | −0.3%next day +0.1% · 5 days +4.5% | ↗ |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $384 | Hold | −11.2% | Reiterated | 23.09.26on TipRanks 07:15 | −0.3%next day +0.1% · 5 days +4.5% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $405 | Hold | −6.4% | Reiterated | 23.09.26on TipRanks Sep 22 11:00 | +4.4%next day −0.3% · 5 days +4.5% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $450 | Buy | +4.0% | Reiterated | 22.09.26on TipRanks Sep 23 08:55 | +4.4%next day −0.3% · 5 days +4.5% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $362 | Hold | −16.3% | Reiterated | 22.09.26on TipRanks Sep 23 06:15 | +4.4%next day −0.3% · 5 days +4.5% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $317 | Sell | −26.7% | Reiterated | 22.09.26on TipRanks Sep 23 04:45 | +4.4%next day −0.3% · 5 days +4.5% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $452 | Buy | +4.5% | Reiterated | 22.09.26on TipRanks 14:30 | +4.4%next day −0.3% · 5 days +4.5% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 22.09.26on TipRanks 11:16 | +4.4%next day −0.3% · 5 days +4.5% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $435 | Hold | +0.6% | Assigned | 22.09.26on TipRanks 06:10 | +4.4%next day −0.3% · 5 days +4.5% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $440 → $430−2.3% | Buy | −0.6% | Assigned | 17.09.26on TipRanks 09:10 | −0.2%next day +1.4% · 5 days +6.1% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $380 | Hold | −12.1% | Reiterated | 17.09.26on TipRanks 04:35 | −0.2%next day +1.4% · 5 days +6.1% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $450 | Hold | +4.0% | Reiterated | 16.09.26on TipRanks Sep 17 09:16 | +0.6%next day −0.2% · 5 days +5.8% | ↗ |
| Morten Herholdt★★★★★★★★★★#4305 · hits 69% · avg +8.7% | HSBC | $445 → $425−4.5% | Hold | −1.7% | Downgrade | 09.09.26on TipRanks 20:25 | −1.6%next day −2.2% · 5 days −1.3% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $450 → $442−1.8% | Buy | +2.2% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $456 → $440−3.5% | Buy | +1.7% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $439 → $432−1.6% | Buy | −0.1% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $411 → $419+1.9% | Hold | −3.1% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $439 → $432−1.6% | Buy | −0.1% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $450 → $432−4.0% | Buy | −0.1% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $400 | Hold | −7.5% | Reiterated | 05.09.26on TipRanks Sep 8 08:35 | −9.5%next day 0.0% · 5 days −3.3% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $460 | Buy | +6.4% | Assigned | 18.08.26on TipRanks Aug 19 08:50 | +2.1%next day +3.8% · 5 days +4.8% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $303 → $352+16.2% | Hold | −18.6% | Reiterated | 17.08.26on TipRanks 12:30 | +1.5%next day +2.1% · 5 days +7.6% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $343 → $388+13.1% | Hold | −10.3% | Reiterated | 07.08.26on TipRanks Aug 10 07:25 | +0.9%next day +1.6% · 5 days +0.6% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $350 | Hold | −19.1% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | −0.6%next day +0.9% · 5 days +2.0% | ↗ |
| Courtney Breen★★★★★★★★★★#1339 · hits 85% · avg +18.9% | Bernstein | $335 → $345+3.0% | Hold | −20.2% | Reiterated | 05.08.26on TipRanks Aug 6 07:50 | +4.8%next day −0.6% · 5 days +1.7% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $400 → $450+12.5% | Buy | +4.0% | Reiterated | 05.08.26on TipRanks 07:55 | +4.8%next day −0.6% · 5 days +1.7% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $370 → $400+8.1% | Buy | −7.5% | Reiterated | 05.08.26on TipRanks 07:40 | +4.8%next day −0.6% · 5 days +1.7% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $215 → $230+7.0% | Sell | −46.8% | Reiterated | 05.08.26on TipRanks 07:35 | +4.8%next day −0.6% · 5 days +1.7% | ↗ |
| Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% | Freedom Capital Markets | $375 | Buy | −13.3% | Upgrade | 07.05.26on TipRanks 08:40 | −0.3%next day 0.0% · 5 days −0.1% | ↗ |
| Hans Engel★★★★★★★★★★#1835 · hits 58% · avg +11.1% | Erste Group | — | Hold | — | Downgrade | 05.05.26on TipRanks 06:25 | +1.0%next day −0.9% · 5 days 0.0% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 01.05.26on TipRanks 10:45 | −5.0%next day −1.4% · 5 days −1.8% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $400 | Buy | −7.5% | Reiterated | 22.01.26on TipRanks 04:35 | +0.5%next day −0.7% · 5 days −1.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Amgen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $401 at a price of $422 (−4.8%); now: $403 at $432 (−6.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 18 | 18 | 13 | 16 | 23 | 23 |
| Hold | 19 | 18 | 15 | 20 | 29 | 32 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $5.77 (from $5.47 to $6.07). Last quarter: $6.29.
Sales
Next quarter’s sales estimate — $10.1B (from $9.8B to $10.3B). Last quarter: $10.1B.
Best top-analyst consensus in the sector · Healthcare
About Amgen
- CEO: Robert A. Bradway
- Employees: 31,500
- One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, US
- www.amgen.com
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Comp
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗